Delayed
Börse Stuttgart
11:32:11 05/06/2024 am IST
|
5-day change
|
1st Jan Change
|
0.0778
EUR
|
-20.29%
|
|
-1.01%
|
-35.79%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
44.31
|
32.42
|
52.01
|
38.52
|
15.64
|
25.42
|
Enterprise Value (EV)
1 |
40.1
|
35.29
|
43.74
|
30.57
|
11.19
|
29.61
|
P/E ratio
|
-4.84
x
|
-1
x
|
66.7
x
|
-6
x
|
-0.76
x
|
-1.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
7.23
x
|
7.56
x
|
29.3
x
|
9.48
x
|
10.8
x
|
14.1
x
|
EV / Revenue
|
6.54
x
|
8.23
x
|
24.6
x
|
7.53
x
|
7.75
x
|
16.4
x
|
EV / EBITDA
|
-11.8
x
|
-3.69
x
|
-5.69
x
|
-5.52
x
|
-0.66
x
|
-1.57
x
|
EV / FCF
|
-7.11
x
|
-8.03
x
|
-4.87
x
|
-4.16
x
|
-3.83
x
|
-3.01
x
|
FCF Yield
|
-14.1%
|
-12.5%
|
-20.5%
|
-24.1%
|
-26.1%
|
-33.2%
|
Price to Book
|
1.02
x
|
1.97
x
|
1.79
x
|
1.17
x
|
0.7
x
|
1.72
x
|
Nbr of stocks (in thousands)
|
50,815
|
58,407
|
77,977
|
91,722
|
1,11,059
|
1,54,077
|
Reference price
2 |
0.8720
|
0.5550
|
0.6670
|
0.4200
|
0.1408
|
0.1650
|
Announcement Date
|
09/04/19
|
27/04/20
|
23/04/21
|
28/04/22
|
29/04/23
|
02/05/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
6.127
|
4.289
|
1.776
|
4.062
|
1.443
|
1.8
|
EBITDA
1 |
-3.385
|
-9.564
|
-7.69
|
-5.535
|
-17.04
|
-18.92
|
EBIT
1 |
-3.527
|
-9.795
|
-7.814
|
-5.582
|
-17.11
|
-19.05
|
Operating Margin
|
-57.56%
|
-228.37%
|
-439.98%
|
-137.42%
|
-1,185.93%
|
-1,058.5%
|
Earnings before Tax (EBT)
1 |
-11.16
|
-36.05
|
1.846
|
-5.837
|
-19.28
|
-20.33
|
Net income
1 |
-9.399
|
-33.73
|
1.089
|
-5.937
|
-19.56
|
-20.34
|
Net margin
|
-153.4%
|
-786.38%
|
61.32%
|
-146.16%
|
-1,355.65%
|
-1,130.22%
|
EPS
2 |
-0.1800
|
-0.5531
|
0.0100
|
-0.0700
|
-0.1850
|
-0.1505
|
Free Cash Flow
1 |
-5.636
|
-4.395
|
-8.974
|
-7.357
|
-2.919
|
-9.833
|
FCF margin
|
-91.99%
|
-102.47%
|
-505.3%
|
-181.11%
|
-202.27%
|
-546.3%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/04/19
|
27/04/20
|
23/04/21
|
28/04/22
|
29/04/23
|
02/05/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
2.87
|
-
|
-
|
-
|
4.18
|
Net Cash position
1 |
4.21
|
-
|
8.27
|
7.95
|
4.45
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-0.3005
x
|
-
|
-
|
-
|
-0.2212
x
|
Free Cash Flow
1 |
-5.64
|
-4.4
|
-8.97
|
-7.36
|
-2.92
|
-9.83
|
ROE (net income / shareholders' equity)
|
-19.7%
|
-108%
|
4.71%
|
-19.2%
|
-70.9%
|
-110%
|
ROA (Net income/ Total Assets)
|
-3.12%
|
-12.1%
|
-11.6%
|
-7.01%
|
-22.2%
|
-30.4%
|
Assets
1 |
301.3
|
277.9
|
-9.38
|
84.72
|
87.93
|
66.94
|
Book Value Per Share
2 |
0.8500
|
0.2800
|
0.3700
|
0.3600
|
0.2000
|
0.1000
|
Cash Flow per Share
2 |
0.2100
|
0.0900
|
0.1900
|
0.2000
|
0.1300
|
0.0400
|
Capex
1 |
0.05
|
0.03
|
0.12
|
0.14
|
0.49
|
0.18
|
Capex / Sales
|
0.73%
|
0.61%
|
6.7%
|
3.42%
|
33.82%
|
10.17%
|
Announcement Date
|
09/04/19
|
27/04/20
|
23/04/21
|
28/04/22
|
29/04/23
|
02/05/24
|
Last Close Price
0.1162
EUR Average target price
1.2
EUR Spread / Average Target +932.70% Consensus |
1st Jan change
|
Capi.
|
---|
| +42.83% | 75TCr | | +34.11% | 61TCr | | -5.70% | 36TCr | | +18.06% | 33TCr | | +4.63% | 29TCr | | +17.02% | 25TCr | | +9.26% | 21TCr | | -4.21% | 21TCr | | +2.43% | 17TCr |
Other Pharmaceuticals
|